Please see profiles on each of the Directors below:
Andrew Joy (Chairman)
Andrew Joy joined the Board in March 2012 and became chairman in July 2016. He was one of the founding Partners of Cinven, a leading private equity firm investing in Europe and U.S. He is a Senior Advisor of Stonehage Fleming Group, Chairman of the investment committee of FPE Capital and is a trustee of several charities. Mr Joy has been Chairman or Director of numerous growing companies over the past 30 years. He is former Chairman of the BVCA (British Venture Capital and Private Equity Association) and Director of the EVCA.
Geoff Hsu joined the Board in May 2018. He is a General Partner of OrbiMed, having joined in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as an analyst in the healthcare investment banking group at Lehman Brothers. Mr. Hsu received his A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Prior to business school, he spent two years studying medicine at Harvard Medical School.
Steven Bates was appointed to the Board in July 2015 and is Chairman of the Management Engagement Committee. He is the Chairman of Vietnam Opportunities Fund and of F&C Capital and Income Investment Trust. Other directorships held by him include British Empire Trust plc and GuardCap Asset Management Ltd. He has a wealth of experience as an investment manager and sits on or is adviser to various committees in the wealth management and pension fund areas. Previously he was head of global emerging markets at JP Morgan Asset Management.
Professor Dame Kay Davies, CBE
Professor Dame Kay Davies CBE joined the Board in March 2012. She is Chair of the Remuneration Committee and is the senior Independent Director. Professor Davies is the Dr Lee’s Professor of Anatomy and Associate Head of the Medical Sciences Division at the University of Oxford and a fellow of Hertford College. She is also a Co-Director of the Oxford Neuromuscular Centre, and a director of biopharmaceutical company, UCB Pharma S. A.
Professor Davies also serves on the GRL Board (Sanger Institute) and the Genome England Board (NHS).
Lord Willetts joined the Board in November 2015. He is Executive Chairman of the Resolution Foundation and a Visiting Professor at King's College London. He is Governor of the Ditchley Foundation, a member of the Council of the Institute for Fiscal Studies and a Board member of the Francis Crick Institute. Lord Willetts is also Chairman of the GRL Board (Sanger Institute). He was Minister for Universities and Science from 2010-2014. He was the Member of Parliament for Havant from 1992-2015. Before that, Lord Willetts worked at HM Treasury and the Number 10 Policy Unit. He also served as Paymaster General in John Major's Government.
Julia Le Blan
Julia Le Blan joined the Board in July 2016 and is Chairman of the Audit Committee. A Chartered Accountant, she has worked in the financial services industry for over 30 years. She was formerly a tax partner at Deloitte and sat for two terms on the AIC's technical committee. Julia is a non-executive director of F&C UK High Income Trust plc, Impax Environmental Markets plc, JP Morgan US Smaller Companies Investment Trust plc and Aberforth Smaller Companies Trust plc.
All Directors, with the exception of Geoff Hsu, are members of the Audit, Management Engagement, Nominations and Remuneration Committees.
Read about the anti-bribery and corruption policies here.
Read about the Company's zero-tolerance approach to the criminal facilitation of tax evasion here.